Cytokinetics opened lower at $58.30, compared with its previous close of $58.53. In the last trading session, the stock traded between $55.67 and $58.58. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Cytokinetics is now worth
$ 142.07
Giving a profit of
$ 42.07 (42.07%)
Note: Past profits do not guarantee future returns.
Rating from 16 Analysts
Today's Change
$-2.40 (-4.10%)
Day High
$58.58
Day Low
$55.67
Day Open
$58.30
Prev Close
$58.53
Volume
13,63,808
1W Return
-12.57%
1M Return
-10.62%
3M Return
-26.59%
6M Return
-24.72%
1Y Return
-15.59%
Market Cap ($ Mn)
7,819
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-61.43%
EPS (TTM)
$-1.37
1 Week
-12.57%
1 Month
-10.62%
3 Months
-26.59%
6 Months
-24.72%
9 Months
-15.97%
Citigroup raises Cytokinetics target to $105, maintains Buy
Citigroup maintains Buy rating on Cytokinetics Inc. Price target raised to $105 from $99. Analyst Eric Joseph leads the upgrade in valuation. Contrasts with Leerink Partners' recent $100 target.
7 days agoCytokinetics posts $47.6M Q3 revenue as MyCorzo sales rise 76% sequentially
Total revenue reached $47.6 million in Q3, up from $1.9 million in Q3 2025. MyCorzo net product revenue hit $44.5 million, a 76% sequential increase. SG&A expenses rose to $113.1 million due to commercial launch costs. Cash and investments stood at $1.6 billion at quarter-end. PDUFA decision for MAPLE-HCM expected on November 14.
8 days agoCytokinetics to report Q3FY27 results on November 4, 2026
Cytokinetics scheduled to release Q3 2026 results on November 4, 2026. Conference call set for 4:30 pm ET with archived replay available for six months. Company plans Supplemental New Drug Application for aficamten in Q4 2026.
22 days agoCytokinetics grants equity awards to 29 new employees
Granted 60,465 stock options and 40,084 RSUs to 29 new employees. Stock options priced at $63.92 per share, equal to closing price on Oct 15, 2026. RSUs vest over 3 years (40%, 40%, 20%) while options vest over 4 years. Grants made as material inducements under Nasdaq Listing Rule 5635(c)(4).
24 days agoHC Wainwright maintains Buy rating on Cytokinetics with $140 target
HC Wainwright analyst Joseph Pantginis reiterated Buy rating. Price target maintained at $140 per share. Analyst view remains unchanged from previous assessment.
24 days agoCytokinetics gets Health Canada nod for MYQORZO in oHCM treatment
Health Canada approves MYQORZO for adult patients with NYHA class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This marks the fifth global regulatory approval for the drug in less than a year, following nods from FDA, NMPA, EC, and MHRA. Phase 3 SEQUOIA-HCM trial showed peak oxygen uptake increased by 1.76 mL/kg/min with MYQORZO versus no change with placebo. Serious adverse events were lower in the MYQORZO group (5.6%) compared to placebo (9.3%), though hypertension rates were higher.
24 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Cytokinetics is now worth
$ 142.07
Giving a profit of
$ 42.07 (42.07%)
Note: Past profits do not guarantee future returns.
